Partner Headlines - GSK

  1. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  2. Pharmaceutical Stocks For Income, Value, And Growth Investors

    Benzinga
  3. New Glaxo bribery inquiries

    IBD
  4. Race for Vaccines, Treatments as West Africa Ebola Death Toll ...

    Benzinga
  5. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  6. GlaxoSmithKline

    IBD
  7. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  8. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  9. Glaxosmithkline Confirms Warning Letter Received from FDA o March ...

    Benzinga
  10. GSK buys up Indonesia unit

    IBD
  11. GSK Recalls Alli in U.S. After Package Tampering

    FoxBusiness
  12. GSK, FDA Probe Tampering of Weight-Loss Drug Alli

    FoxBusiness
  13. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  14. Market Wrap For March 20: Investors Showing No Post-Fed Decision ...

    Benzinga
  15. Glaxo Cancer Vaccine Fails, Testing Continues

    FoxBusiness
  16. Morning Market Losers

    Benzinga
  17. US Stock Futures Drop Ahead Of Jobless Claims Report

    Benzinga
  18. Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does ...

    Benzinga
  19. T. Rowe Price's Brian Rogers Joins GuruFocus for Q&A - Ask an ...

    GuruFocus
  20. T. Rowe Price CIO Brian Rogers Joins GuruFocus for Q&A - Ask ...

    GuruFocus
  21. Gilead's HCV Challengers Near The Starting Gate

    IBD
  22. Brian Rogers of T. Rowe Price Joins GuruFocus for Q&A - Ask a ...

    GuruFocus
  23. Gilead's HCV Challengers Near The Starting Gate

    IBD
  24. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  25. A HIV shot could replace pills

    IBD
  26. Why Long-Term Investor Warren Buffett's Company Just Sold 2 Stocks

    GuruFocus
  27. GlaxoSmithKline, Kinder Morgan And Others Insiders Have Been ...

    Benzinga
  28. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  29. Berkshire Hathaway Files SEC 13F

    Benzinga
  30. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  31. Novartis' 'Cliffy' Business

    GuruFocus
  32. Glaxo expects to retain lead

    IBD
  33. Benzinga Weekly Preview: Twitter To Release Earnings For The ...

    Benzinga
  34. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  35. Tweedy Browne Global Value Fund New Buy and Adds

    GuruFocus
  36. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  37. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  38. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  39. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  40. Morning Market Losers

    Benzinga
  41. Benzinga's Top #PreMarket Losers

    Benzinga
  42. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  43. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  44. Stock Futures Positive, Steady; Netflix Dives On Downgrade

    IBD
  45. New Drugs Could Change Cancer Landscape In 2014

    IBD
  46. ObamaCare = Drug Maker Assistance Act

    YCharts
  47. Why MasterCard, Up 64% in 2013, Isn’t Done

    YCharts
  48. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  49. Prosensa Comments on Drisapersen Program Update

    Benzinga
  50. Merck Collaborates with GlaxoSmithKline on MK-3475

    Benzinga
  51. Glaxo Curbs Drug Promotion

    IBD
  52. Pharma’s Pay-to-Delay Deals Targeted Again

    YCharts
  53. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
  54. Europe Cracks Down on Pharma Pay-to-Delay Deals

    YCharts
  55. Positive data for asthma drug

    IBD
  56. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  57. Breast Cancer Drug Data Boosts Puma Biotechnology

    IBD
  58. Medicines Co. Acquires Rempex Pharma; Street Applauds

    IBD
  59. Pharma Stocks: R&D Spend and Returns

    YCharts
  60. After Top-Seller Remicade: Analysis of J&J’s Future

    YCharts
  61. Takeda Pharmaceutical

    IBD
  62. GlaxoSmithKline CEO in China

    IBD
  63. Isis Pharmaceuticals Earns $2M Milestone Payment from GSK for ...

    Benzinga
  64. Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx, ...

    Benzinga
  65. Pharma Tactic in Europe Under Regulatory Fire

    YCharts
  66. Sanofi Continues to Struggle on Its Path to Recovery

    GuruFocus
  67. What's Warren Buffett Up To?

    GuruFocus
  68. 2013 3Q 13F Roundup

    Benzinga
  69. Warren Buffett's Berkshire Hathaway Buys Exxon Mobil, DaVita, ...

    GuruFocus
  70. Pharmacyclics Drug Wins One Approval, Awaits Another

    IBD
  71. Sarepta Plunges And Love Affair Ends (For Now)

    YCharts
  72. GSK heart drug disappoints

    IBD
  73. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  74. Stocks Open Narrowly Lower; Dean Foods Dives On Q3 Miss

    IBD
  75. GSK Pivotal Phase III Study of Darapladib in Chronic Coronary ...

    Benzinga
  76. Own Stock In Your Employer? A Grim Story

    YCharts
  77. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  78. Benzinga's M&A Chatter for Wednesday November 6, 2013

    Benzinga
  79. Ligand Pharmaceuticals On Pace For Annual Profit

    IBD
  80. Johnson & Johnson Agrees to $2B DOJ Settlement

    FoxBusiness
  81. Two Mega-Launches in Pharma Industry

    YCharts
  82. AstraZeneca Appoints New CFO as Profit Falls

    FoxBusiness
  83. Research Behind Faster FDA Pharma Approvals

    YCharts
  84. GuruFocus Weekly Dividend Growers Pt. I

    GuruFocus
  85. Penny-Wise, Pharma-Foolish: Upshot of R&D Cuts

    YCharts
  86. Glaxo's China drug sales fall

    IBD
  87. Best Return On Invested Capital In Pharma?

    YCharts
  88. Glaxo Sales Tumble 61% in China Amid Probe

    FoxBusiness
  89. J&J Reporting Q3 Earnings As Sentiment Edges Up

    IBD
  90. FBN at the Forbes Healthcare Summit

    FoxBusiness
  91. Benzinga's Top Initiations

    Benzinga
  92. Johnson & Johnson's

    IBD
  93. How Much Do Analysts Hype Drug Launches?

    YCharts
  94. Top Yields in Berkshire Hathaway's Portfolio

    GuruFocus
  95. J&J Buys Glaxo Drug In Hunt For All-Oral HCV Therapy

    IBD
  96. Drugmaker Akorn Becoming Mighty Oak In Hi-Tech Merger

    IBD
  97. Sarepta Takes The Lead In Muscular Dystrophy Race

    IBD
  98. Patent Cliffs, Patent Lawyers And Pharma’s Miracle

    YCharts
  99. Pharma's Cheerleaders: Drug Reps' Jobs At Risk

    YCharts
  100. Ligand Partner GSK Receives Marketing Authorization from EC for ...

    Benzinga
Trading Center